跳至主要内容
临床试验/NCT01178346
NCT01178346已完成3 期

Health-Related Quality-of-Life and Health-Care Resource Utilization Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

Nabi Biopharmaceuticals27 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2010年7月最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
500
试验地点
27
主要终点
To evaluate the effect of NicVAX vs. placebo on HRQoL over the study period.

研究概览

简要总结

The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who are eligible for randomization or have not reached Week 12 in Nabi-4514 or Nabi-4515 studies.
  • Subjects who agree to participate in health-related quality of life study.

排除标准

  • Subjects who are unable to complete a HRQoL questionnaire because of inability to understand the language or due to mental impairment.

研究组 & 干预措施

NicVAX

Experimental

Experimental vaccine

干预措施: NicVAX vaccine (Biological)

Placebo

Placebo Comparator

Placebo vaccine

干预措施: Placebo (Biological)

结局指标

主要结局

To evaluate the effect of NicVAX vs. placebo on HRQoL over the study period.

时间窗: one year

QoL and health utilization questionnaires will be used to measure this outcome.

次要结局

  • To estimate utility scores for use in further health-economic models.(one year)
  • To evaluate health care resource utilization.(one year)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (27)

Loading locations...

相似试验